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Purpose: The objective of this systematic review
was to assess the clinical efﬁcacy, safety, tolerability,
and health-related quality of life outcomes associated
with management of moderate-to-severe chronic pain
with oxycodone/naloxone and tapentadol, focusing
on the effect of these treatments on patients’ daily
functioning.
Methods: Literature from a wide range of sources,
including Embase, MEDLINE, MEDLINE In-Process,
and the Cochrane Central Register of Controlled Trials,
was searched to identify randomized controlled trials
investigating tapentadol or oxycodone/naloxone for the
treatment of patients with chronic pain. A network meta-
analysis was conducted to determine the relative efﬁcacy
and safety proﬁles of these treatments.
Findings: Oxycodone/naloxone was signiﬁcantly
better than tapentadol with respect to the Patient
Assessment of Constipation Symptoms total score
(risk ratio ¼ –3.60; 95% credible interval, 5.36 to
2.11) and revealed a signiﬁcantly lower risk of
dizziness (risk ratio ¼ 0.72; 95% credible interval,
0.42–0.98). Oxycodone/naloxone was directionally
favored, although not signiﬁcantly superior to tapen-
tadol for headache, fatigue, dry mouth, dyspepsia, and
withdrawals due to lack of efﬁcacy. For the AE
outcomes of constipation, nausea, and vomiting, as
well as pain efﬁcacy and all-cause withdrawals from
studies, tapentadol was directionally favored without
any statistical difference from oxycodone/naloxone.
However, the two treatments were not wholly com-
parable for the evaluation of pain efﬁcacy because of
differences in on-study rescue medication and a higher
baseline pain severity in the tapentadol studies.
Implications: Oxycodone/naloxone offers signiﬁ-
cant improvements in Patient Assessment of212Constipation Symptoms total score and dizziness
and was directionally favored for fatigue and head-
ache compared with extended-release tapentadol,
which may translate to improved patient daily func-
tioning and health-related quality of life. (Clin Ther.
2015;37:212–224) & 2015 The Authors. Published by
Elsevier HS Journals, Inc.
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INTRODUCTION
Chronic pain is associated with a wide range of
conditions, including cancer, neuropathic pain, osteo-
arthritis, and other musculoskeletal disorders, and
represents a considerable burden on patients and
health care systems. Prevalence of moderate-to-severe
chronic pain is high, and in a large-scale computer-
assisted telephone survey of 46,394 adults in the
general population across Europe and Israel, 19% of
respondents reported having moderate-to-severe
chronic pain.1 Health care costs associated with
chronic pain are signiﬁcant; therefore, the overall
management of chronic pain represents a substantial
burden to health care systems. In the United States,
chronic pain was estimated to affect approximately
100 million people in 2008 and was associated with
an annual national cost of between $560 billion and
$635 billion.2,3 Studies conducted in Europe also
report a considerable economic burden due to chronicVolume 37 Number 1
*Trademark: Targinacts, Targins, or Targiniqs (Napp Phar-
maceuticals Ltd, Cambridge, United Kingdom).
D. Thakur et al.pain, as indicated by a retrospective study from the
United Kingdom in which patients with chronic lower
back pain reported costs more than double those
incurred by matched controls without chronic lower
back pain (£1074 vs £516, Po0.05).4 Taken together,
patients with chronic pain in the United Kingdom
were reported to account for 4.6 million medical
appointments per year in 2002, which incurred an
overall annual cost of £69 million to the National
Healthcare System.5
The biopsychosocial model of chronic pain is widely
accepted and considers the social and psychological
effects of a condition in addition to a purely biological
perspective. Indeed, chronic pain may involve a complex
combination of physical dysfunction with the beliefs,
coping strategies, illness behaviors, and social interac-
tions of the patient. Therefore, treatment of chronic pain
is often multidisciplinary and multimodal, with the aim
of maximizing pain relief and increasing patient motility,
independence, and quality of life (QoL). Pharmacother-
apy, including opioids, forms an important part of this
multimodal approach.
US guidelines for chronic pain from the Institute for
Clinical Systems Improvement from 2013 recommend
opioids for the treatment of patients with persistent
moderate-to-severe pain in individuals whose pain
is not responsive to initial therapies, as part of an overall
pain management program, and when there
is a favorable risk-beneﬁt proﬁle of prescribing opioids.6
This recommendation was in accordance with the
World Health Organization 3-step ladder treatment
paradigm (developed speciﬁcally for treatment of
chronic pain in patients with cancer), which recom-
mends administering aspirin, acetaminophen, and non-
steroidal anti-inﬂammatory drugs for mild pain, then
escalating treatment to weak opioids (such as codeine or
dihydrocodeine) and ﬁnally to stronger opioids (such as
oxycodone, morphine, or hydromorphone) as necessary
with increasing pain severity.
As a result, opioids are the main treatment option
for patients with moderate-to-severe pain, and a
number of strong opioids are clinically available; for
example, morphine, oxycodone, tapentadol (where
available), hydromorphone, fentanyl, and buprenor-
phine are all widely used. One key drawback of opioid
treatment is the adverse effect (AE) proﬁle, including
headache, dizziness, and fatigue, which can affect
daily functioning and patient QoL.7–9 Another
frequent AE of opioid treatment is opioid-inducedJanuary 2015bowel dysfunction (OIBD), an umbrella term used to
describe the gastrointestinal AEs of opioids, including
constipation, hard dry stools, bloating and abdominal
distension, and abdominal cramps and spasms.10 In a
multinational, Internet-based study of 322 patients
taking daily opioids (PROBE 1), constipation was
reported as the most common AE in 81% of patients,
and it was considered to be the AE that was most
bothersome and most often reported as severe, despite
the use of laxatives in all patients. Because laxatives do
not target the cause of OIBD, they have limited efﬁcacy
in this setting.11 In a survey of OIBD by Pappagallo12
and Kumar et al,13 more than half (54%) of patients
treated with laxatives did not achieve the desired
symptomatic improvement at least 50% of the time.
The AEs experienced by patients treated with opioids,
such as constipation, may lead to dose reduction (which
can affect the effectiveness of their pain relief), reduced
patient adherence, or treatment discontinuation to switch
to a different opioid. Therefore, a need exists for opioid
treatments that offer improved tolerability with
fewer AEs.
Oxycodone is an opioid receptor agonist commonly
used for the treatment of patients with moderate-to-
severe pain. As with other opioids, when used as a
monotherapy, oxycodone stimulates opioid receptors in
the gastrointestinal tract, disrupting normal bowel ac-
tivity and reducing gut motility, resulting in constipa-
tion.14 Naloxone is an opioid antagonist that binds to
opioid receptors in the gut with a higher afﬁnity than
oxycodone, thereby outcompeting oxycodone and
acting directly to prevent AEs, such as constipation
and bowel dysfunction, caused by binding of oxycodone
at these receptors.15 Because of the extensive ﬁrst-pass
metabolism of naloxone in the liver, o3% of the
naloxone dose reaches the systemic circulation and
therefore does not interfere with the analgesic efﬁcacy
of oxycodone. Studies of oxycodone/naloxone (2:1)
have found comparable analgesic efﬁcacy compared
with oxycodone alone.16 The oxycodone/naloxone
combination therefore combines effective analgesia
with improvements in opioid-induced bowel AEs, such
as constipation.15,17 Prolonged-release (PR) oxycodone*
can be given in a ﬁxed-dose combination with naloxone
at a ratio of 2:1.15213
Clinical TherapeuticsThe efﬁcacy of oxycodone/naloxone as an analgesic
with improved gastrointestinal tolerability was revealed
in a number of clinical studies, including randomized
controlled trials (RCTs), an open-label extension study,
and an observational study.16,18–21 A randomized,
double-blind, placebo- and active-controlled study by
Vondrackova et al16 revealed the efﬁcacy of oxycodone/
naloxone as an analgesic, reporting a signiﬁcantly longer
time to recurrence of pain events in this treatment group
compared with placebo (Po0.0003). Furthermore,
signiﬁcant and clinically relevant improvements in
Bowel Function Index scores were found in patients
treated with oxycodone/naloxone compared with
oxycodone in a study by Simpson et al.18 This was
further supported by signiﬁcant improvements in
patient-reported measures of constipation, such as the
stool and rectal subscales of the Patient Assessment
of Constipation Symptoms (PAC-SYM) instrument
(Po0.0001) compared with oxycodone alone.18 A
study by Lowenstein et al19 reported rapid and
signiﬁcant improvement in bowel function in patients
treated with oxycodone/naloxone compared with PR
oxycodone after 4 weeks of treatment (the end of the
study period), and improvements were seen after only 1
week. In an observational study of 588 patients,
treatment with oxycodone/naloxone led to statistically
signiﬁcant improvements in both bowel function and
QoL compared with patients treated with other strong
opioids (Po0.0001 for both outcomes).20 The beneﬁts
of treatment with oxycodone/naloxone were found
during a longer period in a 1-year open-label extension
study, with a mean (SD) Bowel Function Index score
that decreased from 35.6 (27.74) at the start of the
extension study to a normal level (Bowel Function Index
score r28.8) of 20.6 (24.01) after 1 year.21,22
Another prescribed opioid analgesic for chronic pain
is tapentadol†, although it has only recently become
available for use in the treatment of chronic pain after
receiving European Medicines Agency and Food and
Drug Administration approval for use in this indication
in 2011 and is not yet available in every country.
Tapentadol acts both as a μ-opioid receptor agonist
and as a noradrenaline reuptake inhibitor to relieve
pain.23 The efﬁcacy of tapentadol has been found in
preclinical models of nociceptive, neuropathic, visceral,†Trademark: Nucynctas (Janssen Pharmaceuticals Inc, Titus-
ville, NJ) and Palexias (Grünenthal Ltd, Uxbridge, United
Kingdom).
214and inﬂammatory pain and in clinical trials on patients
with nociceptive conditions, including postoperative
orthopedic and abdominal pain and chronic pain due
to osteoarthritis of the hip or knee.23 During these
studies, tapentadol was found to offer comparable
efﬁcacy to other strong opioids.23
There are no published head-to-head RCT data
comparing tapentadol with oxycodone/naloxone in
patients with chronic pain. Therefore, the objective of
this systematic review was to assess the clinical
efﬁcacy, safety, tolerability, and health-related QoL
(HRQoL) outcomes associated with management of
moderate-to-severe chronic pain with oxycodone/
naloxone and tapentadol, focusing on the effect of
these treatments on patients’ daily functioning. In this
systematic review, the safety proﬁles of the 2 treat-
ments were investigated by network meta-analysis
(NMA) to better inform clinicians on the relative risks
and beneﬁts of the 2 treatments and allow decisions
on patient care to be made accordingly.
PATIENTS AND METHODS
Literature Search
A comprehensive search strategy was designed to
retrieve evidence for comparison of oxycodone/nalox-
one with tapentadol in patients with chronic pain. The
review was based on a search of Embase, MEDLINE,
MEDLINE In-Process, and the Cochrane Central
Register of Controlled Trials (Table). In addition to
the database search, abstracts from conference
proceedings were searched, including the Inter-
national Association for the Study of Pain: World
Congress on Pain and the American Academy of Pain
Management. All databases were searched for
literature published between January 2005 and
October 2013 and for abstracts and posters
published in the past 2 years. Bibliographic
searching of included trials and pertinent systematic
reviews was also performed in addition to registry
searches; these registries included the Cochrane
Database of Systematic Reviews and the Database of
Abstracts of Reviews of Effects, European Public
Assessment Reports, and evidence-based reports from
the Agency for Healthcare Research and Quality.
Selection of Studies
To be included in this review, studies had to meet
predeﬁned eligibility criteria. RCT evidence was the
focus of the review and formed the basis of theseVolume 37 Number 1
Table. Data sources used to retrieve the evidence.
Type Source Site
Databases (2005 to
October 2013)
MEDLINE http://www.embase.com/
Embase
MEDLINE In-Process (PubMed in-process
citations)
http://www.ncbi.nlm.nih.gov/sites/entrez
Cochrane Central Register of Controlled
Trials (Cochrane Library)
http://mrw.interscience.wiley.com/
cochrane/cochrane_search_fs.html
Conferences (2012 to
2013)
IASP: World Congress on Pain (2012)
American Academy of Pain Management (2012–2013)
Additional sources Bibliographic searching of pertinent SRs Cochrane Database of Systematic Reviews
Database of Abstracts of Reviews of Effects
Registry search European public assessment reports
Evidence-based reports in AHRQ
AHRQ ¼ Agency for Healthcare Research and Quality; IASP ¼ International Association for the Study of Pain; SR ¼
systematic review.
D. Thakur et al.analyses because evidence from RCTs represents the
gold standard of clinical evidence. Only articles
published in English were included.
The patient population of interest in this review
comprised adult patients of any race or sex with
moderate-to-severe chronic cancer and noncancer
pain. To be included, studies had to evaluate either
oxycodone/naloxone or tapentadol extended release
(ER) for the treatment of chronic pain; any included
interventions in these studies were considered suitable
comparators, such as oxycodone controlled release
(CR) and placebo. Patients receiving placebo may
have received symptomatic treatment for break-
through pain; however, the placebo arm was not a
true placebo. Studies investigating immediate-release
(IR) formulations were excluded from this review, and
only studies evaluating licensed doses of tapentadol
ER and oxycodone CR were included in the analysis.
Bibliographic details and abstracts of all citations
detected by the literature search were extracted and
duplicates of citations due to overlap in coverage of
databases were excluded.Validity Assessment
All abstracts identiﬁed during searches were re-
viewed, and those that did not fulﬁll the eligibility
criteria were excluded. Full-text copies of allJanuary 2015references that fulﬁlled the criteria or for which it
was not possible to include or exclude citations based
on the abstract were reviewed, and the eligibility
criteria were reapplied.
Data were extracted from all studies that met the
eligibility criteria. Review and data extraction for all
citations were performed independently by 2 re-
viewers, and any disagreements were resolved by a
third independent reviewer. Where more than one
publication was identiﬁed describing a single trial, the
data were compiled into a single entry in the data
extraction table to avoid double counting of patients,
and each publication was referenced to be easily
recognizable when more than one publication con-
tributed to the entry.
All included RCTs were assessed for quality of
evidence by means of a study grade and Jadad score.24
The risk of bias among included RCTs was evaluated
using the German, French, and English health
technology assessment checklists.25–27Statistical Analysis
For analysis of each outcome, studies were assessed
for baseline comparability to rule out the effect of
clinical heterogeneity. No study was excluded based
on differences in the baseline characteristics from the
overall studies included in the analyses. Studies with215
Clinical Therapeuticsan enriched or seeded trial design were initially not
included in analyses; in such trials, patients received
active treatment during the open-label titration phase,
after which patients experiencing AEs were excluded,
and only responders were randomized to receive
further treatment. Sensitivity analyses were con-
ducted to explore the effect of including the studies
with enriched randomized withdrawal design into
the NMA.
Bayesian NMA (mixed-treatment comparison),
whereby treatments can be compared in the absence
of head-to-head trials via a common comparator, was
performed if the network consisted of at least one
closed loop, for which direct and indirect evidence
was available for comparison. The NMA was con-
ducted using WINBUGS software that accommodates
evidence from multiarm trials and calculates estimates
using Markov Chain Monte Carlo methods. Point
estimates and 95% credible intervals (CrIs; concep-
tually similar to CIs used in the frequentist approach)RCTs
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Figure 1. Trial flow for the systematic review compa
treatment of chronic pain. n-RCT ¼ nonrando
trial; SGA ¼ subgroup analysis.
216were used to summarize the ﬁndings. Calculations for
each analysis were based on using 70,000 iterations,
discarding the ﬁrst 10,000 iterations.RESULTS
Search Results and Patient Characteristics
Outputs of the literature search were ﬁltered as
illustrated in Figure 1, with only 15 of the 741
citations initially yielded meeting all the criteria for
inclusion after detailed review of the abstracts and
full-text articles. Of the 15 included RCTs, 8 eval-
uated the efﬁcacy and tolerability of tapentadol,28–35
and 7 investigated the efﬁcacy and tolerability of
oxycodone/naloxone.16,18,36–39
Most trials were in Phase III (11 trials), 2 trials
were in Phase II,30,37 and 1 trial was in Phase IV.39
The phase of one trial was unclear.36 Among the 15
included studies, 2 studies used an enriched or seeded
trial design.30,31n-RCTs
(n=24 studies)
 studies
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Review objective (n=51)
ring tapentadol with oxycodone/naloxone for the
mized controlled trial; RCT ¼ randomized controlled
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D. Thakur et al.All the trials, with the exception of 2, were
conducted in multiple settings internationally. The
study by Cloutier et al36 and the OXN4502 trial39
were conducted at multiple centers in Canada and
the United Kingdom, respectively. The method of
randomization generation and concealment of
allocation were judged to be adequate in 7
trials,28,29,31–33,36,37 whereas in the remaining 8 trials
these were unclear.
Wide variation in sample size was observed across
the studies included in the review. Among the included
studies, sample size ranged from 83 patients36 to 1121
patients.32 The mean age of enrolled participants was
reported in 12 RCTs. The mean (SD) age reported in
the studies ranged from 49.4 (13.2) years33 to 64.3
(9.6) years.37 The mean age of the recruited population
was 455 years across all the studies, except in the
study by Buynak et al33 (49.4 years). The proportion of
females with chronic pain among the included studies
generally ranged from 38.7%35 to 76.3%.29
The included RCTs investigating oxycodone/nalox-
one primarily recruited patients who were receiving
opioids (pretreated) and had moderate-to-severe pain
intensity. In contrast, patients enrolled in the tapenta-
dol studies were diagnosed as having chronic pain of
severe intensity. In addition, 450% of the patients
recruited into tapentadol studies were opioid naive. Of
the 13 studies reporting underlying diseases for
chronic pain, most (76.92%) were investigating oxy-
codone/naloxone or tapentadol for the treatment of
nonmalignant pain.
Pain Intensity and Pain Relief
Analgesic efﬁcacy was reported in 11 of the 15
RCTs included in the review using the Numerical
Rating Scale (NRS) score, which is a commonly used
pain assessment tool in which patients report their
pain severity on a scale of 0 (no pain) to 10 (worst
possible pain). Of these 11 trials, 3 trials were
excluded from the primary analysis—2 with an
enriched trial design and 1 investigating a nonlicensed
dose of tapentadol.28,30,31 However, the mean base-
line NRS score was lower in patients receiving oxy-
codone/naloxone compared with patients receiving
tapentadol (weighted mean [SD] for oxycodone/na-
loxone = 3.56 [1.9]; weighted mean [SD] for tapenta-
dol = 7.1 1.98]) (data not shown).
The reduction in NRS score was not signiﬁcant
between oxycodone/naloxone and oxycodone CRJanuary 2015alone (weighted mean difference [WMD] = 0.06;
95% CrI, 0.43 to 0.29). This result is in line with the
pharmacokinetic properties of naloxone. Because na-
loxone is metabolized extensively in the liver, its
antagonistic effects do not affect the efﬁcacy of the
opioid agonist oxycodone.15 The degree of pain relief
between oxycodone/naloxone and tapentadol was not
statistically signiﬁcant when using the NRS score
(WMD ¼ 0.17; 95% CrI, 0.35 to 0.67). Inclusion
of the 2 seeded trials in the sensitivity analysis did not
have an effect on the trend of these results.30,31
Patients in the placebo arm of the oxycodone/nalox-
one studies received IR oxycodone for breakthrough
pain. Where reported, patients in the placebo arm of
the tapentadol studies received treatment with non-
opioid analgesics for breakthrough pain; however, this
was not explicitly stated for all tapentadol studies.Patient Assessment of Constipation Symptoms
The PAC-SYM was performed in 5 of the 15 RCTs
included in the review, of which 3 investigated
tapentadol and 2 investigated oxycodone/naloxone.
PAC-SYM is a sensitive and validated instrument
designed speciﬁcally to measure constipation. The
instrument comprises 3 domains: stool symptoms,
abdominal symptoms, and rectal symptoms. These
domains are assessed by 12 separate items rated on a
Likert scale (0 indicating absence of symptoms; 1,
mild; 2, moderate; 3, severe; and 4, very severe).40
A statistically signiﬁcant reduction in PAC-SYM
total score (denoting reduction in constipation symp-
toms) was observed with oxycodone/naloxone com-
pared with placebo (WMD ¼ 3.50; 95% CrI, 5.27
to 2.00), oxycodone CR (WMD ¼ 3.86; 95% CrI,
5.62 to 2.37), and tapentadol (WMD ¼ 3.60;
95% CrI, 5.36 to 2.11) (Figure 2A). This result
was statistically signiﬁcant despite the lower weight
assigned to oxycodone/naloxone studies in the review,
which was assigned because of lower patient numbers.
A sensitivity analysis was performed that included the
study by Wild et al32; this study had initially been
excluded because it was a subgroup analysis of
patients with constipation at baseline, and results
may therefore have not been fully reﬂective of the
overall study population. The results of this analysis
also revealed a signiﬁcant reduction in PAC-SYM for
oxycodone/naloxone compared with tapentadol, pla-
cebo, and oxycodone CR. Patients in the placebo arm217
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Figure 2. Summary forest plots comparing oxycodone/naloxone with tapentadol for Patient Assessment of
Constipation Symptoms (PAC-SYM) total score (A), dizziness (B), headache (C), fatigue (D), all-
cause withdrawals (E), and withdrawals because of lack of efficacy (F). CR ¼ controlled release;
CrI ¼ credible interval; OXN ¼ oxycodone/naloxone; RR ¼ risk ratio; WMD ¼ weighted mean
difference.
Clinical Therapeuticsmay have received symptomatic treatment for
breakthrough pain.
Adverse Effects
Dizziness
Of the 15 RCTs included in the review, 11 reported
dizziness as an AE, of which 4 were not included in
the original NMA; 2 did not have enough data to
undertake an analysis,28,35 whereas 2 were excluded
because of enriched withdrawal design and were only
included in the sensitivity analysis.30,31
The NMA found a signiﬁcantly lower risk of
dizziness in patients treated with oxycodone/naloxone218compared with both tapentadol (risk ratio [RR] =
0.72; 95% CrI, 0.42–0.98) and oxycodone CR (RR =
0.68; 95% CrI, 0.40–0.92). Tapentadol was associ-
ated with a signiﬁcantly higher risk of dizziness
compared with placebo (RR = 1.48; 95% CrI, 1.33–
1.62) (Figure 2B). Inclusion of the 2 seeded trials in
the sensitivity analysis did not have an effect on the
trend of these results.30,31
Headache
Headache was reported as an AE in 11 studies, of
which 1 was excluded because data were only avail-
able for the maintenance phase, and 1 were excludedVolume 37 Number 1
D. Thakur et al.from the original analysis because of enriched trial
design.30,31 Of the 8 included studies, 4 each were
investigating tapentadol and oxycodone/naloxone.
Oxycodone/naloxone was directionally favored for
a lower risk of headache compared with both tapen-
tadol (RR = 0.81; 95% CrI, 0.49–1.16) and placebo
(RR = 0.86; 95% CrI, 0.52–1.23), although these
results were not signiﬁcant (Figure 2C). Inclusion of
the 2 seeded trials in the sensitivity analysis did not
have an effect on the trend of these results.30,31
Fatigue
Eight studies reported fatigue as an AE, of which 2
were excluded from the original NMA analysis (one
because of seeded trial design and the other because of
unavailability of safety data throughout the entirety of
the study).30,36 A lower weighting was assigned to
studies in which patients were treated with oxyco-
done/naloxone in the NMA compared with tapentadol
as a result of the lower number of patients in oxy-
codone/naloxone studies (N=728 vs N=4092 for oxy-
codone/naloxone and tapentadol, respectively). Despite
this, oxycodone/naloxone was directionally favored for
a decreased risk of fatigue compared with tapentadol
(RR = 0.75; 95% CrI, 0.37–1.10) and oxycodone CR
(RR = 0.73; 95% CrI, 0.37–1.05) and a similar risk to
placebo (RR = 1.04; 95% CrI, 0.50–1.52) (Figure 2D).
The sensitivity analysis, which included the study using
an enriched enrollment randomized withdrawal
design,30 did not reveal a difference in overall trend,
and results were similar to those of the original analysis.
Other AEs
Other AEs evaluated in the systematic review
included dry mouth, dyspepsia, diarrhea, gastrointes-
tinal AEs, nausea, vomiting, and constipation (re-
ported as an AE). Oxycodone/naloxone was
directionally favored for a lower risk of both dry
mouth (RR ¼ 0.61; 95% CrI, 0.02–1.22) and dys-
pepsia (RR ¼ 0.18; 95% CrI, 0.00–1.57) compared
with tapentadol, although neither result was statisti-
cally signiﬁcant. There was no statistically signiﬁcant
difference between tapentadol and oxycodone/nalox-
one with respect to diarrhea (RR ¼ 1.02; 95% CrI,
0.60–1.59), gastrointestinal AEs (RR ¼ 1.13; 95%
CrI, 0.78–1.70), nausea (RR ¼ 1.06; 95% CrI, 0.83–
1.28), vomiting (RR ¼ 1.16; 95% CrI, 0.93–1.46),
and constipation as an AE (RR ¼ 1.04; 95% CrI,
0.84–1.19).January 2015Although the risk of constipation was directionally
favored for tapentadol, this difference was not statisti-
cally signiﬁcant. Moreover, the measure of constipa-
tion as an AE may be much less sensitive than tools
such as PAC-SYM, which is a validated measure
developed speciﬁcally to measure the severity of
constipation. PAC-SYM scores were signiﬁcantly bet-
ter with oxycodone/naloxone treatment compared
with tapentadol, which is indicative of the beneﬁts
of the addition of naloxone in counteracting the
effects of oxycodone on opioid receptors in the
gastrointestinal tract.
Withdrawals
All-cause withdrawals were reported in 14 of the
15 RCTs reviewed, of which 4 were excluded from the
original analysis: 2 for enriched enrollment with-
drawal design, 1 that investigated a nonlicensed dose
of tapentadol, and 1 that only reported withdrawal
data for the maintenance phase of the study.28,30,31,35
No signiﬁcant difference was found in all-cause
withdrawals in patients treated with oxycodone/na-
loxone compared with patients treated with tapenta-
dol, although oxycodone/naloxone was directionally
favored for a higher risk of all-cause withdrawals
compared with tapentadol (RR = 1.13; 95% CrI,
0.85–1.43) and placebo (RR = 1.13; 95% CrI, 0.85–
1.37) (Figure 2E). Oxycodone/naloxone was directionally
favored for a lower risk of all-cause withdrawal
compared with oxycodone CR (RR ¼ 0.89; 95% CrI,
0.71–1.07).
Withdrawals because of a lack of efﬁcacy were
reported in 13 of the 15 RCTs, of which 4 were
excluded from the analysis (1 investigated a non-
licensed dose of tapentadol, 1 reported data only for
maintenance, and 2 had an enriched withdrawal
design).28,30,31,35 The results of the NMA indicated
that oxycodone/naloxone was directionally favored
for a lower risk of withdrawal because of a lack of
efﬁcacy in comparison with tapentadol, although this
was not statistically signiﬁcant (RR = 0.63; 95% CrI,
0.23–1.34) (Figure 2F). This ﬁnding is in contrast with
the NRS score, in which tapentadol was directionally
favored, but there was no signiﬁcant difference in
efﬁcacy between the 2 treatments.
DISCUSSION
Opioid agonists are a mainstay for treatment of
chronic pain but are associated with signiﬁcant219
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pation, and other gastrointestinal effects. As such,
treatments that offer improvements on any of the AE
parameters can provide considerable beneﬁt to the
patient and may improve daily functioning. Oxy-
codone/naloxone and tapentadol are opioid therapies
commonly prescribed for chronic pain, and there is a
need for comparative evidence given the current
absence of head-to-head data. In this systematic
review, we investigated the comparative efﬁcacy
and safety of oxycodone/naloxone and tapentadol
across all types of chronic pain and conducted
mixed-treatment comparisons to quantitatively com-
pare the 2 treatments. This study identiﬁed clear
clinical beneﬁts associated with oxycodone/naloxone;
however, the efﬁcacy and safety proﬁle of oxyco-
done/naloxone may have been underestimated be-
cause of certain limitations of this analysis, for
example, variability in patient populations included
in the studies and the use of opioids as rescue
medication for patients in the placebo arm.
Although the ﬁndings from the NMA indicated
that although the WMD in the NRS score (a patient-
reported pain scale) directionally favored tapentadol
over oxycodone/naloxone, this difference was not
statistically signiﬁcant. In addition, because of vari-
ability in the patient populations between treatments,
the result for oxycodone/naloxone may be an under-
estimate of the treatment’s true efﬁcacy. In the studies
included in this review that investigated the toler-
ability and efﬁcacy of tapentadol, patients were
primarily experiencing pain of severe intensity,
whereas all patients treated with oxycodone/nalox-
one had received prior opioid treatment and were
experiencing moderate-to-severe pain. This was re-
ﬂected in a higher mean baseline NRS score for
patients who received tapentadol compared with
those who received oxycodone/naloxone. Cepeda
et al41 found that patient-described pain relief corre-
lates with initial pain intensity; therefore, patients
with more severe pain may perceive a greater change
in NRS score than patients with less severe pain at
baseline, even if both patients obtained similar
degrees of pain relief.41 As such, the more severe
intensity of pain experienced at baseline by patients
treated with tapentadol may have affected the
comparison of analgesic efﬁcacy in this NMA,
leading to an underestimation of the efﬁcacy of
oxycodone/naloxone.220Improvements in AEs associated with opioids can
have a signiﬁcant effect on the daily functioning of
patients, and improvements in symptoms such as
constipation, dizziness, and headache may therefore
lead to an associated increase in HRQoL in pa-
tients.7,11,42 The ﬁndings from this NMA indicated
that oxycodone/naloxone was signiﬁcantly better than
all other treatments included in the NMA, including
tapentadol, with respect to the patient-reported con-
stipation measure PAC-SYM total score. A common
symptom for patients treated with opioids is OIBD, in
particular constipation, which has a signiﬁcant effect
on QoL; therefore, improvements in constipation with
oxycodone/naloxone, as indicated in this NMA by a
reduction in PAC-SYM total score compared with
tapentadol, may translate to signiﬁcant QoL beneﬁts
for patients.
Oxycodone/naloxone also had a signiﬁcantly lower
risk of dizziness compared with tapentadol, despite
studies in patients treated with oxycodone/naloxone
being assigned a lower weighting in the NMA for
dizziness compared with studies investigating tapenta-
dol. This signiﬁcant improvement in patient-reported
constipation and dizziness with oxycodone/naloxone
is likely to have a considerable effect on daily
functioning of patients being treated with opioids for
chronic pain.
Dizziness can negatively affect patient daily
functioning and social relationships, especially in
an aged population, and is generally associated
with social isolation, functional disability, falls,
and nursing home placement.42 Dizziness can
also affect the social functioning of patients and
may lead to psychological symptoms, including
depression, anxiety, and avoidance behavior.43 In
a study of 2064 randomly selected people aged 18 to
64 years, nearly half of those who had experienced
dizziness reported some degree of handicap as a
result (47%), whereas a similar proportion (46%)
reported anxiety and/or avoidance behavior.43
Further evidence of the effect of dizziness on the
mood and well-being of patients was provided by a
cross-sectional study, which revealed a high degree
of correlation between scores of patients on the
Dizziness Handicap Inventory and the Hospital
Anxiety and Depression Scale, and patients with
higher Dizziness Handicap Inventory scores were
signiﬁcantly more likely to have abnormal scores on
the anxiety and depression subscales of the HospitalVolume 37 Number 1
D. Thakur et al.Anxiety and Depression Scale (P o 0.01 in all
cases).44
Dizziness may also affect the ability of patients to
follow a normal routine, their performance at work,
or their ability to drive a car, which may have a
signiﬁcant effect on their QoL. In a study of 565
home-dwelling individuals aged 76 years in Sweden
(of whom one-third of patients reported dizziness),
individuals experiencing dizziness were more likely to
have locomotor disorders, angina, urinary inconti-
nence, stroke or paresis, and mental disorders than
individuals who did not experience dizziness.8
Dizziness was also found to affect QoL in this study,
as measured by the Nottingham Health Proﬁle in all
QoL dimensions and daily life areas except home life
and, in women, social life.8 Improvements in the
safety proﬁle of opioids with respect to dizziness in
patients treated with oxycodone/naloxone could
therefore hold value for patients, leading to
improvements in QoL and reducing risk of falls in
elderly patients.
Oxycodone/naloxone was directionally favored in
the NMA for a lower risk of headache compared with
tapentadol. Headache, although not life-threatening,
is associated with personal and societal burdens of
pain, disability, damaged QoL, and ﬁnancial cost.45
Results of the NMA indicated that risk of headache
was numerically lower with oxycodone/naloxone
compared with tapentadol, and the results of the
sensitivity analysis revealed that even when the
results of the 2 seeded trials were included, the trend
remained the same. Therefore, in patients with chronic
pain who receive opioids, improvements in headache
with oxycodone/naloxone may offer patients QoL
beneﬁts and improve the tolerability of opioid
treatment when compared with tapentadol.
The risk of fatigue was directionally favored in the
NMA for oxycodone/naloxone when compared with
patients treated with tapentadol, despite the lower
weighting assigned to studies investigating oxycodone/
naloxone because of lower patient numbers in these
studies. Tapentadol was also associated with a sig-
niﬁcantly higher risk of fatigue compared with pla-
cebo and an equivalent risk of fatigue compared with
oxycodone CR. In contrast to tapentadol, although
oxycodone/naloxone was associated with an equiva-
lent risk of fatigue when compared with placebo, it
was directionally favored for a lower risk of fatigue
when compared with oxycodone CR. Fatigue canJanuary 2015similarly lead to serious impairment in QoL, social
activities, and the ability to go to work,9 and
fatigue as a result of treatment may cause loneliness
and social isolation of patients. This may be a
particular problem for elderly patients who may
already experience some degree of social isolation.9
Therefore, potential improvements in fatigue with
oxycodone/naloxone may provide further patient
beneﬁts.
Taken together, the NMA results suggest that
oxycodone/naloxone offers improvements in patient-
reported constipation, dizziness, headache, and fatigue
for patients compared with tapentadol and oxycodone
CR, which may lead to beneﬁts in the daily function-
ing of patients.
In addition to the beneﬁts in AE proﬁle, patients
receiving oxycodone/naloxone were less likely to
withdraw from treatment because of a lack of efﬁcacy
than patients receiving tapentadol, although the differ-
ence was not statistically signiﬁcant. Although a
higher risk of all-cause withdrawals was reported
with oxycodone/naloxone compared with tapentadol,
this was not statistically signiﬁcant. This result may
be explained by the higher number of patients in
the oxycodone/naloxone group receiving opioids at
the time of study enrollment when compared with the
tapentadol group and by the fact that dissatisfaction
with current treatment was a criterion for inclusion in
2 of the tapentadol studies, meaning patients who
received tapentadol may not have been receiving
opioids at enrollment. As such, exposure to opioids
may have been longer in patients treated with oxy-
codone/naloxone.29,33 Long-term evidence from 2
open-label studies of patients who were treated with
oxycodone/naloxone for up to 52 weeks revealed
relatively good safety and tolerability proﬁles with
oxycodone/naloxone, and the reported AEs were
found to be in line with those associated with opioid
treatment.20 In light of this, although withdrawals due
to AEs were numerically higher in patients treated
with oxycodone/naloxone than with tapentadol,
oxycodone/naloxone is tolerable for a longer period
of treatment. Oxycodone/naloxone therefore has
proven tolerability in the long term and may offer
beneﬁts with respect to efﬁcacy compared with
tapentadol.
A separate, recent, indirect treatment comparison
was reported for oxycodone/naloxone and tapenta-
dol.46 Both oxycodone/naloxone and tapentadol were221
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oxycodone CR, and tapentadol was found to be more
cost-effective than oxycodone/naloxone46; however,
that review had a number of methodologic
limitations. Only patients with musculoskeletal pain
were included, thereby signiﬁcantly limiting the scope
of the work, and some studies performed on patients
with musculoskeletal pain within the period were not
included.36 Literature searching was limited to only
MEDLINE and did not include other biomedical
databases. Further limitations in that review
included use of a ﬁxed-effects model as opposed to a
random-effects model (which would consider hetero-
geneity across studies) and the use of qualitative
comparisons using RR values generated from direct
analysis of oxycodone/naloxone and tapentadol with
oxycodone CR as opposed to an indirect treatment
comparison between tapentadol and oxycodone/
naloxone.
As an NMA comparing RCTs with different de-
signs, this systematic review had some limitations that
should be noted. First, the number of patients enrolled
in the tapentadol studies was approximately 3 to 4
times that of patients recruited by studies investigating
oxycodone/naloxone; therefore, studies investigating
oxycodone/naloxone were assigned a lower weight in
the NMA. Second, considerable variability was ob-
served in the patient population recruited across the
RCTs included in this review, with a clear difference
in baseline characteristics between studies looking at
oxycodone/naloxone and tapentadol, which may have
affected the relative assessment of the treatments. Part
of the inclusion criteria for the studies evaluating
oxycodone/naloxone was previous opioid treatment
(pretreated population), and patients in these studies
had constipation caused or aggravated by opioids; in
contrast, this corresponding information was not
reported in studies evaluating tapentadol. Patients
treated with oxycodone/naloxone may have therefore
been treated with opioids for longer durations than
patients treated with tapentadol, potentially leading to
a higher likelihood of AEs. A further difference be-
tween the oxycodone/naloxone and tapentadol studies
relates to the level of pain that patients were experienc-
ing at baseline; patients treated with tapentadol were
experiencing severe pain at baseline, whereas patients
treated with oxycodone/naloxone were experi-
encing moderate-to-severe pain. Furthermore, patients
in the placebo arm of the oxycodone/naloxone studies222received IR oxycodone for breakthrough pain (where
reported, patients in the placebo arm of the tapenta-
dol studies received treatment with nonopioid anal-
gesics for breakthrough pain; however, this was not
explicitly stated for all tapentadol studies). This is
likely to have caused an underestimation of the
efﬁcacy of oxycodone/naloxone as measured by the
NRS score because of the perceived improvement in
pain. Third, the studies investigating tapentadol
enrolled patients who were dissatisﬁed with their
previous treatment and may not have been receiving
opioids at the time of enrollment; therefore, this may
have had an effect on pain intensity scoring between
the tapentadol and oxycodone/naloxone studies.
Therefore, further studies are warranted that compare
oxycodone/naloxone with tapentadol in a head-to-
head RCT.
CONCLUSIONS
Although a certain degree of caution should be taken
with interpretation of these results, given the lack of
head-to-head data comparing tapentadol with oxy-
codone/naloxone and the smaller sample sizes in
oxycodone/naloxone studies, the results of this sys-
tematic review indicate that oxycodone/naloxone of-
fers signiﬁcant improvements in patient-reported
constipation (PAC-SYM) and dizziness. In addition,
oxycodone/naloxone was directionally favored for
fatigue and headache compared with ER tapentadol.
These end points are important when considering the
daily experience of patients with chronic pain. The
results of this study support the value of oxycodone/
naloxone as a key treatment option that may offer
improvements in daily functioning and HRQoL for
patients with chronic pain.
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